Allogene Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

ALLO$0.93-12.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

Common Stock · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · Total Stockholders’ Equity
Shares · Amount
Balance - December 31, 2024	212,210,597	$212	$2,241,879	$(1,819,823)	$(89)	$422,179
Issuance of common stock upon exercise of stock options and vesting of RSU's	2,158,522	2	(2)	—	—	—
Issuance of common stock from ATM offering, net of commissions and offering costs of $0.2 million	3,842,282	4	9,998	—	—	10,002
Stock-based compensation	—	—	12,175	—	—	12,175
Employee stock purchase plan	386,861	1	637	—	—	638
Net loss	—	—	—	(59,733)	—	(59,733)
Net unrealized gain on available-for-sale investments	—	—	—	—	132	132
Balance - March 31, 2025	218,598,262	219	2,264,687	(1,879,556)	43	385,393
Issuance of common stock upon exercise of stock options and vesting of RSUs	398,743	—	—	—	—	—
Issuance of common stock from ATM offering	1,136,871	1	1,513	—	—	1,514
Stock-based compensation	—	—	8,685	—	—	8,685
Net loss	—	—	—	(50,943)	—	(50,943)
Net unrealized loss on available-for-sale investments	—	—	—	—	(88)	(88)
Balance - June 30, 2025	220,133,876	220	2,274,885	(1,930,499)	(45)	344,561
Issuance of common stock upon exercise of stock options and vesting of RSU's	269,915	—	—	—	—	—
Issuance of common stock from ATM offering	2,497,894	3	2,976	—	—	2,979
Stock-based compensation	—	—	8,652	—	—	8,652
Employee stock purchase plan	261,987	—	257	—	—	257
Net loss	—	—	—	(41,400)	—	(41,400)
Net unrealized gain on available-for-sale investments	—	—	—	—	280	280
Balance - September 30, 2025	223,163,672	$223	$2,286,770	$(1,971,899)	$235	$315,329

Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity
Shares · Amount
Balance - December 31, 2023	168,642,238	$169		$2,075,252		$(1,562,233)		$(955)		$512,233
Issuance of common stock upon exercise of stock options and vesting of RSUs	1,551,729	1		793		—		—		794
Vesting of early exercised common stock	—	—		532		—		—		532
Stock-based compensation	—	—		11,924		—		—		11,924
Employee stock purchase plan	259,000	—		856		—		—		856
Net loss	—	—		—		(65,000)		—		(65,000)
Net unrealized gain on available-for-sale investments	—	—		—		—		28		28
Balance - March 31, 2024	170,452,967	170		2,089,357		(1,627,233)		(927)		461,367
Issuance of common stock upon exercise of stock options and vesting of RSUs	415,483	1		18		—		—		19
Stock-based compensation	—	—		13,559		—		—		13,559
Issuance of common stock from ATM offering	250,000	—		1,021		—		—		1,021
Issuance of common stock from registered offering, net of commissions and offering costs of $4.7 million	37,931,035	38		105,245		—		—		105,283
Net loss	—	—		—		(66,358)		—		(66,358)
Net unrealized gain on available-for-sale investments	—	—		—		—		147		147
Balance - June 30, 2024	209,049,485	209		2,209,200		(1,693,591)		(780)		515,038
Issuance of common stock upon exercise of stock options and vesting of RSU's	181,142	—		—		—		—		—
Stock-based compensation			13,387		—		—		13,387
Employee stock purchase plan	269,510	1		678		—		—		679
Net loss	—	—		—		(66,293)		—		(66,293)
Net unrealized gain on available-for-sale investments	—	—		—		—		937		937
Balance - September 30, 2024	209,500,137	$210		$2,223,265		$(1,759,884)		$157		$463,748

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.